Creating antibody treatments that can cross the blood-brain barrier for brain cancer.
Chemical approaches for generating blood-brain barrier-permeable antibody conjugates
This study is working on new ways to help special cancer-fighting drugs reach the brain better, which could lead to more effective treatments for brain tumors and other brain-related conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10889966 on NIH RePORTER |
What this research studies
This research focuses on developing new chemical methods to create antibody-drug conjugates (ADCs) that can effectively penetrate the blood-brain barrier (BBB), which is a significant challenge in treating brain diseases like glioblastoma. The study aims to enhance the delivery of these large molecules to the brain, where they can target and treat cancer cells more effectively. By improving the BBB's permeability, the research seeks to enable systemic therapies that have previously been ineffective due to the barrier's restrictive nature. Patients may benefit from more effective treatments for brain tumors and other central nervous system disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma or other brain tumors who may benefit from improved drug delivery methods.
Not a fit: Patients with brain conditions that do not involve the blood-brain barrier or those who are not candidates for systemic therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for brain cancer and other CNS diseases by allowing drugs to reach their targets in the brain.
How similar studies have performed: While the approach of enhancing BBB penetration is being explored, the specific methods and technologies being developed in this research are novel and have not been widely tested in clinical settings.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Tsuchikama, Kyoji — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Tsuchikama, Kyoji
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.